The expression of miR-21, HSP90α and GASP-1 in serum of patients with lung cancer and their correlation with pathological subtypes

Serum miR-21, HSP90α, GASP-1 in Lung Cancer Subtypes

  • Hongyan Pang
  • Yange Gong
  • Yaojie Wang
  • Lianyong Zhang Cangzhou Central Hospital
DOI: https://doi.org/10.5937/jomb0-48051
Keywords: Lung cancer, Heat shock protein-90α, miR-21, G protein-coupled receptor-associated sorting protein 1, Pathological subtypes

Abstract


Background: To investigate the expression of miR-21, heat shock protein-90α (HSP90α) and G protein-coupled receptor-related sorting protein 1(GASP-1) in the serum of lung cancer patients and their correlation with pathological subtypes.

Methods: Eighty patients with lung cancer were included in the lung cancer group from May 2020 to May 2022, and 40 volunteers who underwent physical examination were randomly included in the control group according to the group ratio of 2:1. Serum miR-21, HSP90α and GASP-1 levels of patients in the two groups were detected. To explore the correlation between it and pathological subtypes, TNM stage and lymph node metastasis of lung cancer patients.

Results: The serum levels of miR-21, HSP90α and GASP-1 in lung cancer group were higher than those in control group (P < 0.05). ROC curve analysis showed that serum miR-21, HSP90α and GASP-1 levels had certain value in the diagnosis of lung cancer, and their AUC values were 0.901, 0.874 and 0.865, respectively (P < 0.05). There was no difference in the relative expression level of serum miR-21 between squamous cell carcinoma group and adenocarcinoma group (P>0.05), but the levels of HSP90α and GASP-1 in adenocarcinoma group were higher than those in squamous cell carcinoma group (P < 0.05). There was no difference in the levels of serum miR-21, HSP90α and GASP-1 between stage I and stage II groups (P>0.05). The levels of serum miR-21, HSP90α and GASP-1 in stage III and stage IV groups were higher than those in stage I and stage II groups, and those in stage IV were higher than those in stage III group (P < 0.05). The serum levels of miR-21, HSP90α and GASP-1 in patients with metastasis were higher than those in patients without metastasis (P < 0.05).

Conclusions: In patients with lung cancer, serum miR-21, HSP90α and GASP-1 levels were increased, which were associated with pathological subtypes, stage and lymph node metastasis, and had high diagnostic significance in the clinic.

References

1. Shi J, Li J, Wang Q, Cheng X, Du H, Han R, et al. The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. Transl Lung Cancer R 2021; 10(10): 3929-42.
2. Candal-Pedreira C, Ruano-Ravina A, Provencio M, Fernandez-Villar A, Perez-Rios M. Lung Cancer Screening Quality Criteria: A Population Perspective. Chest 2021; 160(4): e329-31.
3. Zhang H, Mao F, Shen T, Luo Q, Ding Z, Qian L, et al. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett 2017; 13(2): 669-76.
4. Perotti C, Liu R, Parusel CT, Bocher N, Schultz J, Bork P, et al. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res 2008; 10(6): R94.
5. Zheng X, Chang F, Zhang X, Rothman VL, Tuszynski GP. G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker. Exp Mol Pathol 2012; 93(1): 111-5.
6. Weynants P, Marchandise FX, Sibille Y. Pulmonary perspective: immunology in diagnosis and treatment of lung cancer. Eur Respir J 1997; 10(8): 1703-19.
7. Bade BC, Dela CC. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med 2020; 41(1): 1-24.
8. Maheshwarkar P, Sunder RR. Population exposure across central India to PM(2.5) derived using remotely sensed products in a three-stage statistical model. Sci Rep-Uk 2021; 11(1): 544.
9. Villaruz LC, Blumenschein GJ, Otterson GA, Leal TA. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. Cancer-Am Cancer Soc 2023; 129(9): 1319-50.
10. Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol 2023; 41(6): 1213-27.
11. Peng H, Wu X, Liu S, He M, Tang C, Wen Y, et al. Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil. Clin Transl Med 2023; 13(7): e1340.
12. Okita R, Kawamoto N, Okada M, Inokawa H, Yamamoto N, Murakami T, et al. Preoperative neutrophil-to-lymphocyte ratio correlates with PD-L1 expression in immune cells of patients with malignant pleural mesothelioma and predicts prognosis. Sci Rep-Uk 2023; 13(1): 5263.
13. Shah M, Marmarelis ME, Mamtani R, Hennessy S. Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer 2022; 23(8): 731-6.
14. Guo Y, Li P, Bledsoe G, Yang ZR, Chao L, Chao J. Kallistatin inhibits TGF-beta-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp Cell Res 2015; 337(1): 103-10.
15. Mohapatra S, Calin G. JAM-ming miR-21. Cell Death Differ 2021; 28(10): 2837-9.
16. Kim N, Kim JY, Yenari MA. Anti-inflammatory properties and pharmacological induction of Hsp70 after brain injury. Inflammopharmacology 2012; 20(3): 177-85.
17. Yang T, Wei L, Ma X, Ke H. Columbamine suppresses proliferation and invasion of melanoma cell A375 via HSP90-mediated STAT3 activation. J Recept Sig Transd 2021; 41(1): 99-104.
18. Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, et al. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Brit J Cancer 2017; 116(4): 501-8.
19. Martini L, Thompson D, Kharazia V, Whistler JL. Differential regulation of behavioral tolerance to WIN55,212-2 by GASP1. Neuropsychopharmacol 2010; 35(6): 1363-73.
20. Zheng X, Chang F, Rong Y, Tuszynski GP. G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker, promotes proliferation and invasion of triple negative breast cancer. Exp Mol Pathol 2022; 125: 104751.
21. Rong Y, Torres-Luna C, Tuszynski G, Siderits R, Chang FN. Differentiating Thyroid Follicular Adenoma from Follicular Carcinoma via G-Protein Coupled Receptor-Associated Sorting Protein 1 (GASP-1). Cancers 2023; 15(13): 3404.
Published
2024/02/09
Issue
Ahead of print
Section
Original paper

Copyright (c) 2024 Hongyan Pang, Yange Gong, Yaojie Wang, Lianyong Zhang

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.